“Ultrahuman Home is our step towards integrating environmental awareness into personal health. By continuously monitoring ...

Demonstrated greater α-synuclein reductions compared to other gene therapy approaches ...

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 ...

A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/goldman-sachs-46th-g.... After the event, a ...

Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.

We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “Meta Healthcare Group ...

Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage ...

About ORLADEYO® (berotralstat) ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors.

About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global ...

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 ...

Cost of revenues was RMB35.7 million (US$4.9 million) for the three months ended March 31, 2025, representing a 10.6% decrease from RMB39.9 million for the same period in 2024, primarily due to a ...